Quote:

---

Could the increases in T3 and T4 have led to the improvements in the 350mg dosed patients?

---

Lower T3 and T4 counts can be caused by fat deposits and inflammation and results in thyroid dysregulation. One of the functions of T3 and T4 is to increase metabolism to help burn fat. The increased liver fat deposits decrease T3/T4 which reduces metabolism and further induces fat accumulation. The reversal in fat deposition and inflammation would naturally cause T3 and T4 levels to rise increasing metabolic function.

Resmetirom is actually an artificial form of T3. So it would have an anti-inflammatory/anti-fibrosis effect but I don't think the effect would be as high as with a direct anti-inflammatory/anti-fibrosis agent like leronlimab.

Quote:

---

Through what biomarker would you suspect leronlimab might assist?

---

The levels of T3 and T4 look like they increased substantially so I don't know whether resmetirom would add much benefit.